A tubule cell model for ifosfamide nephrotoxicity

被引:25
作者
Aleksa, K [1 ]
Halachmi, N [1 ]
Ito, S [1 ]
Koren, G [1 ]
机构
[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada
关键词
LLCPK-1; metabolism; ifosfamide; renal; CYP3A; CYP2B;
D O I
10.1139/Y05-036
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Mechanisms leading to ifosfamide (IF)-induced renal damage have not been fully elucidated. Recent work suggests that localized renal tubular metabolism of IF and the production of the nephrotoxic chloroacetaldehyde may lead to nephrotoxicity. Presently no pharmacological method to reduce IF nephrotoxicity has been identified. The objectives of this study were to establish a tubule cell model for IF nephrotoxicity, to verify whether renal proximal tubular cells have the necessary cytochrome P450 (CYP) enzymes to oxidize IF, and whether they can metabolize IF to chloroacetaldehyde. CYP3A, and 2B mRNA and protein were identified in LLCPK-1 cells. The cells metabolized the R- and S-IF enantiomers to their respective 2- and 3-dechloroethylifosfamide metabolites, by-products of chloroacetaldehyde formation. Metabolite production was both time and concentration-dependent. IF did not affect cell viability. In contrast, glutathione-depleted cells showed time and dose-dependent damage. The presence of the relevant CYP enzymes in renal tubular cells along with their ability to metabolize IF to its 2- and 3-dechloroethylifosfamide metabolites suggests that nephrotoxic damage may result from the localized production of chloroacetaldehyde. Glutathione is a major defence mechanism against IF toxicity, thus pharmacological methods for replenishing intracellular glutathione may be effective in modulating IF-induced nephrotoxicity.
引用
收藏
页码:499 / 508
页数:10
相关论文
共 35 条
[1]
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report [J].
Abu-Ghosh, AM ;
Krailo, MD ;
Goldman, SC ;
Slack, RS ;
Davenport, V ;
Morris, E ;
Laver, JH ;
Reaman, GH ;
Cairo, MS .
ANNALS OF ONCOLOGY, 2002, 13 (03) :460-469
[2]
Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: Pharmacokinetic modeling for estimation of intracellular levels [J].
Aleksa, K ;
Ito, S ;
Koren, G .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2004, 143 (03) :159-162
[3]
Developmental renal tubular toxicity: A hypothetical framework and experimental approaches [J].
Aleksa, K ;
Ito, S ;
Koren, G .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2001, 62 (12) :930-941
[4]
Ashraf MS, 1997, MED PEDIATR ONCOL, V28, P62, DOI 10.1002/(SICI)1096-911X(199701)28:1<62::AID-MPO12>3.0.CO
[5]
2-C
[6]
Ifosfamide nephrotoxicity: Limited Influence of metabolism and mode of administration during repeated therapy in paediatrics [J].
Boddy, AV ;
English, M ;
Pearson, ADJ ;
Idle, JR ;
Skinner, R .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (07) :1179-1184
[7]
CHANG TKH, 1993, CANCER RES, V53, P5629
[8]
IFOSFAMIDE MESNA - A REVIEW OF ITS ANTINEOPLASTIC ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN CANCER [J].
DECHANT, KL ;
BROGDEN, RN ;
PILKINGTON, T ;
FAULDS, D .
DRUGS, 1991, 42 (03) :428-467
[9]
Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules [J].
Dubourg, L ;
Tanière, P ;
Cochat, P ;
Baverel, G ;
Michoudet, C .
PEDIATRIC NEPHROLOGY, 2002, 17 (02) :97-103
[10]
Dubourg L, 2001, J AM SOC NEPHROL, V12, P1615, DOI 10.1681/ASN.V1281615